Feature | May 17, 2013

Robotic Angioplasty Achieves 97.6 Percent Clinical Success Rate

Publication of PRECISE Trial Results builds on momentum of FDA clearance and commercialization of the CorPath System.

May 17, 2013 — The Journal of American College of Cardiology has published the results from Corindus Vascular Robotics’ CorPath PRECISE (Percutaneous Robotic-Enhanced Coronary Intervention) study in the April 2013 issue. Results of the trial demonstrate the vascular robotics CorPath System is safe and feasible for patients, with significantly lower harmful radiation exposure to the operator.


The study was a prospective, single-arm, multicenter, open-label, non-randomized study, enrolling 164 patients at nine clinical trial sites.


The primary endpoint of clinical procedural success was achieved in 97.6 percent of patients, and device technical success was achieved in 98.8 percent. Additionally, a secondary endpoint of the trial was the reduction in radiation exposure to the physician. Researchers determined the CorPath System significantly lowered radiation exposure by 95.2 percent compared to levels found when a physician performs the procedure at the patient’s bedside. Although operator comfort was not measured in the study, researchers noted the ability to perform procedures in a seated position without a heavy lead apron provides relief for back discomfort and allows the operator to focus solely on the patient.


Traditionally, angioplasty procedures are performed manually, where an interventional cardiologist inserts a guidewire with a stent or balloon attached to physically open an artery blockage and help improve blood flow. While angioplasty procedures remain one of the most frequently performed procedures in the United States with nearly one million cases annually, the procedure has remained largely unchanged for decades. A CorPath robotic angioplasty allows interventional cardiologists to perform the procedure remotely, away from the patient bedside. Seated in a radiation-protected cockpit, the physician uses a joystick to robotically advance catheters, angioplasty balloons and stents to clear the blockage and restore blood flow. Additionally, the technology provides interventional cardiologists with the ability to accurately measure anatomy and precisely control stents.


“At Sanford Health, we implemented two CorPath Systems in December, and we have already performed 34 procedures. Using a joystick, I am able to advance the catheter millimeter-by-millimeter through the artery and achieve enhanced control when placing the stent,” said Tom Stys, M.D., FACC, FSCAI, medical director at Sanford Heart Hospital and Cardiovascular Services, Sioux Falls, South Dakota. “With an increasing amount of complex procedures being performed, we feel it is essential to invest in new technology that will help physicians provide enhanced patient care.”


For more information: www.corindus.com


Related Content

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Hansen Medical, Magellan 10 French Robotic Catheter, FDA 510(k) clearance
Technology | Robotic Systems| July 29, 2015
The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.
Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
CSI, ViperWire Advance Peripheral Guide Wire with Flex Tip, Stealth, Diamondback

Diamondback 360 Peripheral OAS image courtesy of Cardiovascular Systems Inc.

Technology | Atherectomy Devices| July 22, 2015
Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab| July 22, 2015
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
cardiac rehab after angioplasty, rehabilitation, ACC, Randal J. Thomas, referral
Feature | Cardiac Rehabilitation| July 17, 2015
Hospitals in the Midwest were more likely than others to refer patients for guideline-recommended cardiac...
ACC, health policy statement, heart team, cardiovascular health
Feature | Cardiovascular Surgery| July 17, 2015
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern...
Medtronic, Protege GPS self-expanding peripheral stent, FDA approval
Technology | July 16, 2015
Medtronic plc announced that its Protege GPS self-expanding peripheral stent system has received approval from the U.S...
Overlay Init